{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 329,
  "pageCount": 415,
  "prevPage": 328,
  "nextPage": 330,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a Q&A format to document expert testimony.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/329",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-329",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "I wouldn't say this is something...every patient of mine...should receive...this is still case-by-case...why don't I just trial regular diazoxide...[it has] the same kind of pharmacological profile as DCCR...I will probably just trial normal diazoxide and see what happens.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b3-181d8caecbdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "Lack of patient and physician enthusiasm; will likely just trial generic diazoxide instead",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa25557b-c042-4671-ad79-8c38f16cd54b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.47
      },
      "kind": "paragraph",
      "text": "Sees ~40 PWS patients and key role in developing PWS treatment guidelines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb7d63a0-b512-4afe-a537-0f4aed226491",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "TAM is “at most” 10% of PWS patients; only 10-15% would even trial it",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee86bb42-6f91-4e18-9d30-26123d56e164",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.86,
        "x": 0.07,
        "y": 0.5
      },
      "kind": "quote",
      "text": "“I am a pediatric endocrinologist. I have a multidisciplinary Prader-Willi clinic, and you probably already saw that I was a lead author, chair for developing the [redacted] guidance for children and young adults for Prader-Willi Syndrome...I see about 40 patients with Prader-Willi Syndrome...” -Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01bc3a2e-0ba6-47e7-b68f-05bac1625111",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.79
      },
      "kind": "quote",
      "text": "Q: “How much enthusiasm do you sense from other doctors or patients? Were people like, it’s approved, I have to use it?”\nA: “No. The day it got approved, I happened to have a clinic. A couple of patients said, oh, this is great news. It’s got FDA approval. At that time, we weren’t aware of the cost. I wouldn’t say this is something that every child or every patient of mine with Prader-Willi syndrome should receive this treatment. This is still on a case-by-case patient basis. And again, some of the younger ones are managed very well and don’t need it. However, would I be able to allow and be able to justify that cost? That’s probably the biggest issue. And then, as physicians, all it’s going to take is somebody to actually say, you know what? I can’t afford that. Why don’t I just trial regular diazoxide. The drug therapy has got the same kind of pharmacological profile as DCCR. I will probably just trial normal diazoxide and see what happens.” -Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1eb985e9-5655-48e0-bffa-11348513ce45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.86,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "quote",
      "text": "Q: “Let’s say we’re two years, five years out. It sounds like you don’t like the price and aren’t sure if it works. What percentage of Prader-Willi patients, within two years, five years out, do you really think are going to be on this drug?”\nA: “I suppose 10% to 15% would probably trial it.”\nQ: “So, you think, at most, the total addressable market is about 10% of patients?”\nA: “At most.” -Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70f6b98b-b7b7-4c38-8914-2f047a477848",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "I am a pediatric endocrinologist. I have a multidisciplinary Prader-Willi clinic, and you probably already saw that I was a lead author, chair for developing the [redacted] guidance for children and young adults for Prader-Willi Syndrome...I see about 40 patients with Prader-Willi Syndrome...I suppose 10% to 15% would probably trial it...At most...No. The day it got approved, I happened to have a clinic. A couple of patients said, oh, this is got news. It's got FDA approval. At that time, we weren't aware of the cost. I wouldn't say this is something that every child or every patient of mine with Prader-Willi syndrome should receive this treatment. This is still on a case-by-case patient basis. And again, some of the younger ones are managed very well and don't need it. However, would I be able to allow and be able to justify that cost? That's probably the biggest issue. And then, as physicians, all it's going to take is somebody to actually say, you know what? I can't afford that. Why don't I just trial regular diazoxide. The drug therapy has got the same kind of pharmacological profile as DCCR. I will probably just trial normal diazoxide and see what happens. — Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b3-1d538375c2ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6544219e-8f39-4d8c-8695-f4dd0c97135f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #7: Author on Soleno papers and a key opinion leader with ~40 PWS patients at one of the largest clinics; developed the PWS treatment guidelines. Participated in the phase 3, open-label, and withdrawal studies. Indicated tepid interest in the field toward Vykat and that the TAM is “at most” 10% of PWS patients, with possibly 10-15% of patients who may “trial it” over the next two to five years. Stated the cost is unjustifiable given limited benefit, and that he would rather just use generic diazoxide suspension instead: “I wouldn’t say this is something...every patient of mine...should receive...this is still case-by-case...why don’t I just trial regular diazoxide...[it has] the same kind of pharmacological profile as DCCR...I will probably just trial normal diazoxide and see what happens.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adb0097e-1628-4a8e-ab08-12926c57b17f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}